FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation.
Oncologist
; 23(12): 1520-1524, 2018 12.
Article
in En
| MEDLINE
| ID: mdl-30120160
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Erdheim-Chester Disease
/
Proto-Oncogene Proteins B-raf
/
Vemurafenib
/
Antineoplastic Agents
Type of study:
Clinical_trials
/
Observational_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
America do norte
Language:
En
Journal:
Oncologist
Year:
2018
Document type:
Article